v3.26.1
Revenues and geographic information
 6 Months Ended
Jun. 30, 2026
Disclosure of revenues and geographic information [abstract]  
Revenues and geographic information
9. Revenues and geographic information
Net sales to third parties
Net sales to third parties by region1
Second quarter
Q2 2026
USD m
Q2 2025
USD m
% change
USD
% change
cc2
Q2 2026
% of total
Q2 2025
% of total
   US
5 954
6 249
-5
-5
41
44
   Europe
4 441
4 170
6
4
31
30
   Asia/Africa/Australasia
3 018
2 713
11
11
21
19
   Canada and Latin America
995
922
8
3
7
7
Total
14 408
14 054
3
1
100
100
   Of which in established markets
10 536
10 537
0
0
73
75
   Of which in emerging growth markets
3 872
3 517
10
6
27
25
 
 1  Net sales to third parties by location of customer. Emerging growth markets comprise all markets other than the established markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. Novartis definition of Western Europe includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
 2  Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.
First half
H1 2026
USD m
H1 2025
USD m
% change
USD
% change
cc2
H1 2026
% of total
H1 2025
% of total
   US
10 913
11 961
-9
-9
40
44
   Europe
8 627
8 075
7
1
31
30
   Asia/Africa/Australasia
6 038
5 485
10
8
22
20
   Canada and Latin America
1 943
1 766
10
5
7
6
Total
27 521
27 287
1
-2
100
100
   Of which in established markets
19 798
20 206
-2
-4
72
74
   Of which in emerging growth markets
7 723
7 081
9
4
28
26
 1  Net sales to third parties by location of customer. Emerging growth markets comprise all markets other than the established markets of the US, Canada, Western Europe, Japan, Australia and New Zealand. Novartis definition of Western Europe includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
 2  Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.
Net sales to third parties by core therapeutic area and established brands
Second quarter
Q2 2026
Q2 2025
% change
% change
USD m
USD m
USD
cc1
Cardiovascular, renal and metabolic
Entresto
1 181
2 357
-50
-51
Leqvio
480
298
61
59
Vanrafia
27
nm
nm
Total cardiovascular, renal and metabolic
1 688
2 655
-36
-37
Immunology
Cosentyx
1 824
1 629
12
10
Ilaris
550
477
15
15
Xolair 2
342
443
-23
-25
Rhapsido
64
nm
nm
Total immunology
2 780
2 549
9
8
Neuroscience
Kesimpta
1 424
1 077
32
32
Zolgensma Group
365
297
23
20
Aimovig
88
83
6
3
Total neuroscience
1 877
1 457
29
28
Oncology
Kisqali
1 695
1 177
44
43
Pluvicto
651
454
43
43
Jakavi
576
524
10
8
Tafinlar + Mekinist
581
573
1
0
Scemblix
562
298
89
89
Lutathera
225
207
9
8
Fabhalta 3
225
120
88
88
Total oncology 4
4 515
3 353
35
34
Established brands
Sandostatin Group
302
303
0
-1
Exforge Group
191
191
0
-3
Promacta/Revolade 4
179
502
-64
-65
Diovan Group
160
154
4
2
Tasigna 4
142
327
-57
-58
Lucentis
126
173
-27
-30
Myfortic 4
105
102
3
0
Piqray/Vijoice 4
123
111
11
10
Kymriah
88
99
-11
-10
Contract manufacturing
472
276
71
68
Other 4
1 660
1 802
-8
-9
Total established brands 4
3 548
4 040
-12
-14
 
Total net sales to third parties
14 408
14 054
3
1
 1  Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.
 2  Net sales to third parties reflect Xolair sales for all indications.
 3  Net sales to third parties reflect Fabhalta sales for all indications.
 4  Reclassified to conform with 2026 presentation of brands by therapeutic area and established brands.
    
nm = not meaningful
Net sales to third parties by core therapeutic area and established brands
First half
H1 2026
H1 2025
% change
% change
USD m
USD m
USD
cc1
Cardiovascular, renal and metabolic
Entresto
2 486
4 618
-46
-48
Leqvio
932
555
68
64
Vanrafia
43
nm
nm
Total cardiovascular, renal and metabolic
3 461
5 173
-33
-35
Immunology
Cosentyx
3 390
3 163
7
5
Ilaris
1 025
896
14
13
Xolair 2
730
899
-19
-22
Rhapsido
101
nm
nm
Total immunology
5 246
4 958
6
3
Neuroscience
Kesimpta
2 588
1 976
31
29
Zolgensma Group
667
624
7
3
Aimovig
183
159
15
8
Total neuroscience
3 438
2 759
25
22
Oncology
Kisqali
3 211
2 133
51
48
Pluvicto
1 293
825
57
55
Jakavi
1 133
1 016
12
6
Tafinlar + Mekinist
1 074
1 125
-5
-7
Scemblix
995
536
86
85
Lutathera
436
400
9
8
Fabhalta 3
394
201
96
94
Total oncology 4
8 536
6 236
37
34
Established brands
Sandostatin Group
589
620
-5
-7
Exforge Group
394
370
6
2
Promacta/Revolade 4
363
1 048
-65
-66
Diovan Group
310
304
2
-2
Tasigna 4
297
704
-58
-59
Lucentis
230
362
-36
-40
Myfortic 4
216
201
7
4
Piqray/Vijoice 4
204
211
-3
-4
Kymriah
169
199
-15
-16
Contract manufacturing
824
619
33
27
Other 4
3 244
3 523
-8
-11
Total established brands 4
6 840
8 161
-16
-19
 
Total net sales to third parties
27 521
27 287
1
-2
 1  Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.
 2  Net sales to third parties reflect Xolair sales for all indications.
 3  Net sales to third parties reflect Fabhalta sales for all indications.
 4  Reclassified to conform with 2026 presentation of brands by therapeutic area and established brands.
    
nm = not meaningful
Net sales to third parties1 of the top 20 brands in 2026
Second quarter
US
Rest of world
Total
Brands
Brand classification by therapeutic area or established brands
Key indications
USD m
% change USD/cc2
USD m
% change USD
% change cc2
USD m
% change USD
% change cc2
Cosentyx
Immunology
Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS)
1 069
16
755
7
3
1 824
12
10
Kisqali
Oncology
HR+/HER2- metastatic breast cancer and early breast cancer
1 045
39
650
52
49
1 695
44
43
Kesimpta
Neuroscience
Relapsing forms of multiple sclerosis (MS)
942
32
482
32
30
1 424
32
32
Entresto
Cardiovascular, renal and metabolic
Chronic heart failure, hypertension
-2 5
nm
1 183
4
3
1 181
-50
-51
Pluvicto
Oncology
PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane
493
38
158
65
62
651
43
43
Jakavi
Oncology
Myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GvHD)
576
10
8
576
10
8
Tafinlar + Mekinist
Oncology
BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG)
197
-20
384
17
15
581
1
0
Ilaris
Immunology
Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)
315
21
235
8
8
550
15
15
Scemblix
Oncology
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation
369
93
193
80
82
562
89
89
Leqvio
Cardiovascular, renal and metabolic
Atherosclerotic cardiovascular disease (ASCVD)
214
55
266
66
63
480
61
59
Xolair 3
Immunology
Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA)
342
-23
-25
342
-23
-25
Zolgensma Group
Neuroscience
Spinal muscular atrophy (SMA)
152
58
213
6
2
365
23
20
Sandostatin Group
Established brands
Carcinoid tumors, acromegaly
177
-5
125
8
7
302
0
-1
Lutathera
Oncology
GEP-NETs gastroenteropancreatic neuroendocrine tumors
163
9
62
9
6
225
9
8
Exforge Group
Established brands
Hypertension
191
1
-3
191
0
-3
Fabhalta 4
Oncology
Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G)
124
63
101
130
130
225
88
88
Promacta/Revolade
Established brands
Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)
39
-83
140
-49
-50
179
-64
-65
Diovan Group
Established brands
Hypertension
6
-14
154
5
3
160
4
2
Tasigna
Established brands
Chronic myeloid leukemia (CML)
30
-81
112
-32
-34
142
-57
-58
Lucentis
Established brands
Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)
126
-27
-30
126
-27
-30
Top 20 brands total
5 333
-7
6 448
10
8
11 781
2
1
Rest of portfolio
621
14
2 006
4
2
2 627
6
5
Net sales to third parties
5 954
-5
8 454
8
6
14 408
3
1
 1  Net sales to third parties by location of customer
 2  Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.
 3  Net sales to third parties reflect Xolair sales for all indications.
 4  Net sales to third parties reflect Fabhalta sales for all indications.
 5  Mainly due to change in revenue deductions
    
nm = not meaningful
Net sales to third parties1 of the top 20 brands in 2026
First half
US
Rest of world
Total
Brands
Brand classification by therapeutic area or established brands
Key indications
USD m
% change USD/cc2
USD m
% change USD
% change cc2
USD m
% change USD
% change cc2
Cosentyx
Immunology
Psoriasis (PsO), ankylosing spondylitis (AS), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSPA), hidradenitis suppurativa (HS)
1 839
6
1 551
9
3
3 390
7
5
Kisqali
Oncology
HR+/HER2- metastatic breast cancer and early breast cancer
1 970
47
1 241
56
49
3 211
51
48
Kesimpta
Neuroscience
Relapsing forms of multiple sclerosis (MS)
1 666
28
922
36
31
2 588
31
29
Entresto
Cardiovascular, renal and metabolic
Chronic heart failure, hypertension
70
-97
2 416
9
5
2 486
-46
-48
Pluvicto
Oncology
PSMA-positive mCRPC patients post-ARPI, pre- and post-Taxane
999
55
294
63
55
1 293
57
55
Jakavi
Oncology
Myelofibrosis (MF), polycythemia vera (PV), graft-versus-host disease (GvHD)
1 133
12
6
1 133
12
6
Tafinlar + Mekinist
Oncology
BRAF V600+ metastatic and adjuvant melanoma, advanced non-small cell lung cancer (NSCLC), tumor agnostic with BRAF mutation indication, pediatric low grade glioma (pLGG)
367
-19
707
5
1
1 074
-5
-7
Ilaris
Immunology
Auto-inflammatory (CAPS, TRAPS, HIDS/MKD, FMF, SJIA, AOSD, gout)
561
17
464
11
7
1 025
14
13
Scemblix
Oncology
Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation
655
90
340
78
76
995
86
85
Leqvio
Cardiovascular, renal and metabolic
Atherosclerotic cardiovascular disease (ASCVD)
380
43
552
90
83
932
68
64
Xolair 3
Immunology
Severe allergic asthma (SAA), chronic spontaneous urticaria (CSU), nasal polyps, food allergy (FA)
730
-19
-22
730
-19
-22
Zolgensma Group
Neuroscience
Spinal muscular atrophy (SMA)
269
20
398
0
-6
667
7
3
Sandostatin Group
Established brands
Carcinoid tumors, acromegaly
339
-12
250
6
2
589
-5
-7
Lutathera
Oncology
GEP-NETs gastroenteropancreatic neuroendocrine tumors
314
9
122
10
5
436
9
8
Exforge Group
Established brands
Hypertension
2
-33
392
7
2
394
6
2
Fabhalta 4
Oncology
Paroxysmal Nocturnal Hemoglobinuria (PNH), IgA Nephropathy (IgAN), Adult C3 Glomerulopathy (C3G)
223
74
171
134
128
394
96
94
Promacta/Revolade
Established brands
Immune thrombocytopenia (ITP), severe aplastic anemia (SAA)
64
-88
299
-44
-46
363
-65
-66
Diovan Group
Established brands
Hypertension
16
-20
294
4
0
310
2
-2
Tasigna
Established brands
Chronic myeloid leukemia (CML)
58
-84
239
-31
-34
297
-58
-59
Lucentis
Established brands
Age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO)
230
-36
-40
230
-36
-40
Top 20 brands total
9 792
-10
12 745
11
6
22 537
1
-2
Rest of portfolio
1 121
3
3 863
1
-3
4 984
1
-2
Net sales to third parties
10 913
-9
16 608
8
4
27 521
1
-2
 1  Net sales to third parties by location of customer
 2  Constant currencies (cc) is a non-IFRS measure. A definition of non-IFRS measures used by Novartis can be found starting on page 43.
 3  Net sales to third parties reflect Xolair sales for all indications.
 4  Net sales to third parties reflect Fabhalta sales for all indications.
Other revenues
(USD millions)
Q2 2026
Q2 2025
H1 2026
H1 2025
Profit sharing income
456
356
788
613
Royalty income 1
27
318
53
326
Milestone income
5
35
18
89
Other 2
55
73
95
141
Total other revenues
543
782
954
1 169
 1  In the second quarter and first half of 2025, royalty income includes a royalty settlement of USD 0.3 billion.
 2  Other includes revenue from activities such as manufacturing or other services rendered, to the extent such revenue is not recorded under net sales to third parties.